Equity Analyst, LightStream Research

Shifara Samsudeen, ACMA, CGMA

A chartered management accountant with more than 10 years of rich experience in investment research and financial analysis. Worked as an equity analyst for one of the world's largest asset managers with USD2.5trn in AUM covering numerous sectors including chemicals, retail, tech, autos, telco, real-estate and banks, globally. Experienced in fundamental equity research, industry research, commodity studies, forensic accounting, and due diligence reviews.

Equity Analyst

New Horizon Health IPO Valuation: Healthy Valuation

IFast 4Q2020 Results: Higher AUA Growth Drives Strong Earnings

Suzhou Basecare Medical IPO Valuation: Attractive Even at the Upper End of the IPO Pricing

Cloopen Group IPO: Seems to Follow the Right Path to Profits

New Horizon Health IPO: Aiming to Become Pioneer in Cancer Screening

Suzhou Basecare Medical IPO: First Mover with the Only NMPA-Approved PGT Product in China

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

Equity Capital Markets

New Horizon Health  / Equity Capital Markets

<a href="https://www.smartkarma.com/entities/new-horizon-health-limited" target="_blank" data-smartkarma-citation="entities:31039:1" rel="noopener">New Horizon Health (NHH HK)</a>  operates in the Chinese colorectal cancer screening market. The company’s proprietary cancer screening product, ColoClear is the first and only molecular cancer screening test approved by the NMPA.In addition to the company’s proprietary screening test, ColoClear, the company also has Pupu Tube, a non-invasive, stool-based FIT test, which is the first self-conducted FIT screening product approved by the NMPA in China.The company has filed for an IPO to list its shares on the Hong Stock Exchange and according to the Bloomberg, the company plans to raise about US$300m.In our previous insight on the company’s IPO, we discuss the company’s business, its product pipeline and outlook. In this follow-up insight, we have highlighted and discussed some of the key new data points from the company’s Post Hearing Information Pack (PHIP).

New Horizon Health (NHH HK)  operates in the Chinese colorectal cancer screening market. The company’s proprietary cancer screening product, ColoClear is the first and only molecular cancer screening test approved by the NMPA.In addition to the company’s proprietary screening test, ColoClear, the company also has Pupu Tube, a non-invasive, stool-based FIT test, which is the first self-conducted FIT screening product approved by the NMPA in China.The company has filed for an IPO to list its shares on the Hong Stock Exchange and according to the Bloomberg, the company plans to raise about US$300m.In our previous insight on the company’s IPO, we discuss the company’s business, its product pipeline and outlook. In this follow-up insight, we have highlighted and discussed some of the key new data points from the company’s Post Hearing Information Pack (PHIP).

New Horizon Health

New Horizon Health IPO: PHIP Updates